surmount 1 tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Tirzepatide after intensive lifestyle intervention
Pay in 4 interest-free payments of $7.25 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21




















![AIR JORDAN RETRO 9 - SLIM JENKINS [USED] runner](https://cdn.shopify.com/s/files/1/0081/7548/5013/products/SLIM.jpg?v=1571713756)



